CD318 expression defines a novel subset of human CD8 + regulatory T cells
Science Advances · 2026
DOI: 10.1126/sciadv.adz4203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Jeong-Su Do und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Theranostics, City of Hope, Duarte, CA, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust, Wanek Family Foundation to Cure Type Diabetes Innovative, Margie and Robert Petersen Foundation.
Abstract (Originalsprache)
CUB domain–containing protein 1 (CDCP1; CD318) is a surface glycoprotein known as a ligand for CD6, primarily studied in tumor immunology where it associates with poor prognosis. CD318 is expressed in myeloid dendritic cells and activated monocytes associated with immunoregulatory functions. Here, selective expression of CD318 on a subset of activated human CD8 + T cells, but not CD4 + T cells, is shown, defining suppressor function of this cell population. CD318 + CD8 T cells exhibited reduced PD-1 and KLRG-1 expression, diminished interferon-γ and tumor necrosis factor–α production, and potent suppression of autologous CD4 and CD8 T cell activation in vitro. Notably, CD8 T cells from patients with type 1 diabetes (T1D) showed reduced CD318 induction compared with controls. Mechanistically, CD318 inhibited T cell receptor signaling independently of SHP2, while its induction required interleukin-2–dependent mTOR activation. These findings identify CD318 as a marker of human CD8 + T cells with implications for immune regulation and autoimmunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Theranostics, City of Hope, Duarte, CA, USA.
- Beckman Research Institute and Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
- Irell & Manella Graduate School of Biological Sciences, City of Hope, Duarte, CA, USA.
- Department of Translational Research and Cellular Therapeutics, City of Hope, Duarte, CA, USA.
- IBMC - Instituto de Biologia Molecular e Celular, Porto, Portugal.
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
ORCID-Profile: Jeong-Su Do, Wei-Kai Chen, Angel Gu, Helena Reijonen
Förderung
- Leona M. and Harry B. Helmsley Charitable Trust
- Wanek Family Foundation to Cure Type Diabetes Innovative
- Margie and Robert Petersen Foundation
Zitieren
APA
Do, J. S., Chen, W. K., Hung, Y. W., Arribas-Layton, D., Lu, C., Gu, A., Montero, E., Carmo, A. M., & Reijonen, H. (2026). CD318 expression defines a novel subset of human CD8 + regulatory T cells. Science Advances. https://doi.org/10.1126/sciadv.adz4203
Vancouver
Do JS, Chen WK, Hung YW, Arribas-Layton D, Lu C, Gu A, et al. CD318 expression defines a novel subset of human CD8 + regulatory T cells. Science Advances. 2026. doi:10.1126/sciadv.adz4203
BibTeX
@article{Do2026,
author = {Do, Jeong-Su and Chen, Wei-Kai and Hung, Yu-Wen and Arribas-Layton, David and Lu, Congcong and Gu, Angel and Montero, Enrique and Carmo, Alexandre M and Reijonen, Helena},
title = {CD318 expression defines a novel subset of human CD8 + regulatory T cells},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.adz4203}
}
EUVIMED